NOT FOR DISTRIBUTION
Header cover image

Quantum Health Group

Market Cap

€43.3m

Last Updated

2021/04/14 17:33 UTC

Data Sources

Company Financials

Executive Summary

Quantum Health Group Limited distributes medical imaging and patient treatment equipment and services in Australia, Thailand, South Korea, Vietnam, New Zealand, the Philippines, and China. More Details


Snowflake Analysis

Flawless balance sheet with proven track record.

Share Price & News

How has Quantum Health Group's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: QD4 is more volatile than 90% of German stocks over the past 3 months, typically moving +/- 26% a week.

Volatility Over Time: QD4's weekly volatility has decreased from 32% to 26% over the past year, but is still higher than 75% of German stocks.


Market Performance


7 Day Return

31.7%

QD4

0.9%

DE Healthcare

0.2%

DE Market


1 Year Return

107.9%

QD4

0.6%

DE Healthcare

42.4%

DE Market

Return vs Industry: QD4 exceeded the German Healthcare industry which returned 0.6% over the past year.

Return vs Market: QD4 exceeded the German Market which returned 42.4% over the past year.


Shareholder returns

QD4IndustryMarket
7 Day31.7%0.9%0.2%
30 Day51.9%5.2%5.1%
90 Day27.4%-2.9%9.6%
1 Year107.9%107.9%2.6%0.6%47.0%42.4%
3 Year295.0%295.0%-27.9%-31.4%23.5%12.8%
5 Year464.3%464.3%-28.5%-33.1%51.0%29.5%

Long-Term Price Volatility Vs. Market

How volatile is Quantum Health Group's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Quantum Health Group undervalued compared to its fair value and its price relative to the market?

13.3%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: QD4 (€0.04) is trading below our estimate of fair value (€0.05)

Significantly Below Fair Value: QD4 is trading below fair value, but not by a significant amount.


Price To Earnings Ratio

PE vs Industry: QD4 is good value based on its PE Ratio (11.8x) compared to the DE Healthcare industry average (32.5x).

PE vs Market: QD4 is good value based on its PE Ratio (11.8x) compared to the German market (28.2x).


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate QD4's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: QD4 is overvalued based on its PB Ratio (1.8x) compared to the DE Healthcare industry average (1.7x).


Future Growth

How is Quantum Health Group forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

13.2%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Quantum Health Group has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Past Performance

How has Quantum Health Group performed over the past 5 years?

54.5%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: QD4 has high quality earnings.

Growing Profit Margin: QD4's current net profit margins (9.5%) are higher than last year (7.2%).


Past Earnings Growth Analysis

Earnings Trend: QD4's earnings have grown significantly by 54.5% per year over the past 5 years.

Accelerating Growth: QD4's earnings growth over the past year (50.3%) is below its 5-year average (54.5% per year).

Earnings vs Industry: QD4 earnings growth over the past year (50.3%) exceeded the Healthcare industry 2%.


Return on Equity

High ROE: QD4's Return on Equity (15.3%) is considered low.


Financial Health

How is Quantum Health Group's financial position?


Financial Position Analysis

Short Term Liabilities: QD4's short term assets (A$37.4M) exceed its short term liabilities (A$27.6M).

Long Term Liabilities: QD4's short term assets (A$37.4M) exceed its long term liabilities (A$1.1M).


Debt to Equity History and Analysis

Debt Level: QD4's debt to equity ratio (18.8%) is considered satisfactory.

Reducing Debt: QD4's debt to equity ratio has reduced from 66% to 18.8% over the past 5 years.

Debt Coverage: QD4's debt is well covered by operating cash flow (81.3%).

Interest Coverage: QD4's interest payments on its debt are well covered by EBIT (17.1x coverage).


Balance Sheet


Dividend

What is Quantum Health Group current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate QD4's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate QD4's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if QD4's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if QD4's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of QD4's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

17.4yrs

Average board tenure


CEO

John Walstab (57 yo)

4.17yrs

Tenure

AU$308,294

Compensation

Mr. John Andrew Walstab has been Managing Director of Quantum Health Group Limited (formerly known as Quantum Energy Limited) since February 7, 2017 and serves as its Chief Executive Officer and Company Se...


CEO Compensation Analysis

Compensation vs Market: John's total compensation ($USD235.12K) is below average for companies of similar size in the German market ($USD470.48K).

Compensation vs Earnings: John's compensation has been consistent with company performance over the past year.


Board Members

Experienced Board: QD4's board of directors are seasoned and experienced ( 17.4 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Quantum Health Group Limited's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Quantum Health Group Limited
  • Ticker: QD4
  • Exchange: DB
  • Founded: 1975
  • Industry: Health Care Distributors
  • Sector: Healthcare
  • Market Cap: AU$67.698m
  • Listing Market Cap: AU$43.277m
  • Shares outstanding: 1.13b
  • Website: https://www.qhealthcare.com.au

Number of Employees


Location

  • Quantum Health Group Limited
  • 22 Rosebery Avenue
  • Rosebery
  • New South Wales
  • 2018
  • Australia

Listings


Biography

Quantum Health Group Limited distributes medical imaging and patient treatment equipment and services in Australia, Thailand, South Korea, Vietnam, New Zealand, the Philippines, and China. It operates in t...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/04/14 17:33
End of Day Share Price2021/04/13 00:00
Earnings2020/12/31
Annual Earnings2020/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.